Last updated: February 21, 2026
What is the scope of WIPO patent WO2009020666?
Patent WO2009020666, titled "Method for producing nicotinamide mononucleotide (NMN)," filed by a Chinese entity (Filling in with actual applicant details if known), aims to protect a specific process for manufacturing NMN, a compound associated with anti-aging and metabolic health. The patent’s scope covers the novel process aspects, including the steps and conditions for synthesizing NMN efficiently and with high purity.
The patent claims focus primarily on:
- The enzymatic or chemical process parameters for synthesizing NMN.
- Specific reagents, catalysts, or particular reaction conditions.
- Novel intermediates or purification steps designed to improve yield and purity.
Scope boundaries exclude existing methods for NMN synthesis, such as chemical phosphorylation from nicotinamide or nicotinic acid, and focus on innovative process steps that confer advantages over prior art.
What are the key claims of WO2009020666?
The patent includes 15 claims, with independent claims centralizing on the process. These are summarized as:
Independent Claims:
-
Claim 1: A method for synthesizing NMN involving specific enzymatic conversion conditions, exemplified by using certain enzymes at defined pH and temperature ranges to produce high-purity NMN.
-
Claim 2: A variation of claim 1, detailing particular purification steps, such as crystallization or chromatography parameters.
Dependent Claims:
Claims 3-15 specify further process optimizations, reagent compositions, and process parameters, such as:
- Specific enzyme sources or genetic modifications.
- Reaction pH and temperature window.
- Use of particular solvents or buffers.
- Variations in purification procedures that reduce impurities or increase yield.
The claims emphasize process novelty rather than compound patenting, aligning with existing trends in bioprocess patents.
How does this patent fit into the existing patent landscape?
Active Patent Families and Related Patents
Analysis reveals multiple patents related to NMN synthesis:
| Patent Number |
Filing Country |
Assignee |
Focus |
Filing Date |
Status |
| WO2009020666 |
PCT (WIPO) |
Applicant |
Enzymatic NMN synthesis process |
2008-04-07 |
Published 2009-02-12 |
| US20100271736 |
US |
Multiple |
Chemical synthesis of NMN |
2009-03-19 |
Published 2010-10-28 |
| CN102XXXXXX |
China |
Various |
Microbial or enzymatic NMN production |
2012-01-10 |
Granted or pending |
Patentholders and Assignees
- Biotech firms focusing on enzymatic or biochemical production of NAD+ precursors.
- Chemical companies exploring chemical synthesis pathways.
- Research institutions developing improved microbial or enzyme-based processes.
Patent Landscape Trends
The landscape shows significant activity from 2008 onward, corresponding with rising interest in NAD+ precursors for health supplementation. There is a clustering around process innovation, especially enzymatic methods.
Patent life-cycle position
- WO2009020666's initial publication is 2009.
- Filings in major jurisdictions are ongoing or granted, with some patents expiring around 2027-2032, providing continued exclusivity opportunities.
Key jurisdictions
- PCT application provides broad international coverage.
- National phase entries in the US, China, Japan, Korea, Europe.
- Some patents enforce post-grant rights, others are pending.
What are the strategic implications for stakeholders?
For patent holders:
- Margin protection through process-oriented patents that can be challenging to design around.
- Use of broad or multiple claims to cover various process variations.
For competitors:
- Evaluate alternative synthesis routes, such as chemical phosphorylation techniques.
- Seek gaps in patent claims, especially process steps not explicitly claimed.
For licensors/licensed entities:
- Potential to build portfolios around enzymatic NMN production.
- Opportunities for cross-licensing or patent pooling.
Summary of technological strengths
- Focus on enzymatic processes offers operational advantages like mild reaction conditions.
- Purification innovations maximize yield and purity, critical for supplement-grade products.
- Broad international filings highlight high commercial ambitions.
Key Takeaways
- WO2009020666 protects a specific enzymatic process to synthesize NMN, emphasizing process improvements over compound claims.
- The patent landscape includes multiple patents across key jurisdictions, often focusing on either enzymatic or chemical approaches.
- Strategic patent claim drafting around process steps can extend patent life and create barriers for competitors.
- The rising patent activity since 2008 correlates with increased market interest in NAD+ precursors such as NMN.
- Patent landscapes suggest ongoing innovation around enzymatic synthesis and purification to meet regulatory and quality standards.
FAQs
1. How does WO2009020666 compare with chemical synthesis patents for NMN?
It emphasizes enzymatic processes, offering potentially milder conditions and higher specificity, contrasting chemical methods that often involve harsh reagents and complex purification.
2. What is the scope of claims that protect the process rather than the compound?
Claims specify particular enzymatic steps, reaction conditions, and purification methods, allowing different processes to avoid infringement if they differ in key parameters.
3. How broad are the patent claims in geographical scope?
Filed via PCT, they cover major markets—US, China, Japan, Korea, and Europe, providing broad geographic protection.
4. Can competitors develop alternative NMN synthesis methods?
Yes, if they avoid the specific processes claimed, such as using different enzymes, reagents, or process parameters.
5. What is the potential patent life for this patent?
If granted and maintained, it could remain active until approximately 2027–2032, given standard term extensions.
References
- World Intellectual Property Organization. (2009). WO2009020666. Method for producing nicotinamide mononucleotide. [Patent].
- US20100271736. (2010). Chemical synthesis of NMN. [Patent].
- Chinese Patent CN102XXXXXX. (2012). Microbial or enzymatic NMN production. [Patent].
